Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 30 min ago
Peer-reviewedCC BY-NC-NDBMC gastroenterology

Prognostic value of Gli1 expression on colorectal cancer: a retrospective study.

  • Zhicao Zhang1
  • Jianghong Chen1
  • Yuanhang Ma1
  • Wensheng Wang1
  • Yanni Xiao2
  • Dan Ma3
  1. 1Department of General Surgery, Xinqiao Hospital, Army Medical University, No. 83 Xinqiao Main Street, Shapingba District, Chongqing, 400037, China.
  2. 2111 Project Laboratory of Biomechanics and Tissue Repair, College of Bioengineering, Chongqing University, No. 174 Shazheng Street, Shapingba District, Chongqing, 400030, China.
  3. 3Department of General Surgery, Xinqiao Hospital, Army Medical University, No. 83 Xinqiao Main Street, Shapingba District, Chongqing, 400037, China. [email protected].
Read full textPDFDOICite

Abstract

Background

Circulating tumor cells (CTCs) has been proven to be related to the prognosis of cancer. Nevertheless, there are very few studies on the prognostic significance of CTCs in colorectal cancer (CRC). In this study, we investigated the impact and clinical significance of the number of circulating tumor cells (CTCs) and the expression of glioma-associated oncogene 1 (Gli1) on the prognosis of colorectal cancer (CRC).Methods

This study encompassed a total of 310 colorectal cancer patients who had not received radiotherapy or chemotherapy. Simultaneously, the circulating tumor cells of these 310 patients were isolated and enumerated. The expression of Gli1 in circulating tumor cells (CTCs) was determined by in situ hybridization with RNA (RNA-ISH) method. The results were analyzed in combination with the clinical and pathological parameters of the patients as well as their treatment outcomes. Survival analysis was also conducted to determine its prognostic significance.Results

Gli1 expression was found in 23.15% patients at baseline. Patients with Gli1 expression had significantly poorer treatment response and metastasis. Besides, Gli1 on CTCs was an independent prognostic indicator for poorer progression-free survival and overall survival.Conclusions

The study demonstrated that Gli1 expression and CTC count are promising prognostic indicators in patients with CRC. Further studies are needed to clarify the value of integrating the indicator with current clinical strategies in improving the survival of CRC patients.

Related

  1. Predictive and Prognostic Value of Androgen Receptor Expression Across All Molecular Subtypes in Patients with Breast Cancer Who Received Neoadjuvant-Treatment: Single-Center Retrospective Analysis.
    Harun Muğlu, Vedat Buğra Erol, Hakan Özçelik +14
    Breast cancer (Dove Medical Press)Peer-reviewedCC BY-NCFull textOncologyEurope PMC
  2. Prognostic value of the neutrophil-to-lymphocyte ratio in patients with colorectal cancer undergoing chemotherapy: a systematic review and meta-analysis
    Yihui Zhang, Ning Ding, Yingchao Cui +2
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  3. Prognostic Value of a Seven-Factor Risk Stratification System in T3N0 Colon Cancer: A Single-Center Retrospective Study
    Abdussamet Çelebi, Eren Meral, Fırat Akagündüz +11
    Medicina (Kaunas, Lithuania)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. The Prognostic Role of Vimentin Expression in Triple‐Negative Breast Cancer: A Retrospective Cohort Study
    Erwin Danil Yulian, Tantri Hellyanti, Karl Heinz Leonhardt Rowika
    Cancer reports (Hoboken, N.J.)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. The prognostic value of tumour budding for survival in stage II and III colorectal cancer: a systematic review and meta‐analysis
    Yao Shu, Heng Zhang, Alessandro Lugli +2
    HistopathologyPeer-reviewedCC BY-NC-ND 4.0Full text3 citedOncologyPMC

Cite

BibTeXRIS
BibTeX
@article{zhang2026prognostic,
  title = {{Prognostic value of Gli1 expression on colorectal cancer: a retrospective study.}},
  author = {Zhicao Zhang and Jianghong Chen and Yuanhang Ma and Wensheng Wang and Yanni Xiao and Dan Ma},
  journal = {BMC gastroenterology},
  year = {2026},
  month = aug,
  doi = {10.1186/s12876-026-04918-y},
  url = {https://europepmc.org/article/MED/42958071},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Prognostic value of Gli1 expression on colorectal cancer: a retrospective study.
AU  - Zhicao Zhang
AU  - Jianghong Chen
AU  - Yuanhang Ma
AU  - Wensheng Wang
AU  - Yanni Xiao
AU  - Dan Ma
PY  - 2026
DA  - 2026/08/04
JO  - BMC gastroenterology
DO  - 10.1186/s12876-026-04918-y
UR  - https://europepmc.org/article/MED/42958071
AB  - Background  Circulating tumor cells (CTCs) has been proven to be related to the prognosis of cancer. Nevertheless, there are very few studies on the prognostic significance of CTCs in colorectal cancer (CRC). In this study, we investigated the impact and clinical significance of the number of circulating tumor cells (CTCs) and the expression of glioma-associated oncogene 1 (Gli1) on the prognosis of colorectal cancer (CRC).Methods  This study encompassed a total of 310 colorectal cancer patients who had not received radiotherapy or chemotherapy. Simultaneously, the circulating tumor cells of these 310 patients were isolated and enumerated. The expression of Gli1 in circulating tumor cells (CTCs) was determined by in situ hybridization with RNA (RNA-ISH) method. The results were analyzed in combination with the clinical and pathological parameters of the patients as well as their treatment outcomes. Survival analysis was also conducted to determine its prognostic significance.Results  Gli1 expression was found in 23.15% patients at baseline. Patients with Gli1 expression had significantly poorer treatment response and metastasis. Besides, Gli1 on CTCs was an independent prognostic indicator for poorer progression-free survival and overall survival.Conclusions  The study demonstrated that Gli1 expression and CTC count are promising prognostic indicators in patients with CRC. Further studies are needed to clarify the value of integrating the indicator with current clinical strategies in improving the survival of CRC patients.
SN  - 1471-230X
ER  -